Aquestive Therapeutics, Inc. AQST Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s financing cash flow?
- Aquestive Therapeutics, Inc. (AQST) reported financing cash flow of $4.42M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Aquestive Therapeutics, Inc.'s financing cash flow decreased by 78.6% year-over-year, from $20.65M to $4.42M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s financing cash flow has grown at a 35.9% compound annual growth rate (CAGR), from $30.11M to $102.72M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.